46 / 108
S44
Artigo Original
encephalomyelitis. Clin Dev Immunol. 2013;2013:721383.
14. Malaghini M,Thomaz-SoccolV, Probst CM, Krieger MA, Preti H, Kritski A, et
al. Recombinant antigen production for assays of intradermoreaction for diagnosis
and surveillance of tuberculosis. J Biotechnol. 2011 Oct;156(1):56–8.
15. Moreira A da SR, Huf G,Vieira MAM da S, Costa PA da,Aguiar F, Marsico AG,
et al. Liquid vs Solid Culture Medium to Evaluate Proportion andTime to Change
in Management of Suspects ofTuberculosis—A Pragmatic RandomizedTrial in Se-
condary andTertiary Health Care Units in Brazil. DohertyTM, editor. PLOS ONE.
2015 Jun 5;10(6):e0127588.
16. Langley I, Squire SB, Dacombe R, Madan J, e Silva JRL, Barreira D, et al. De-
velopments in Impact Assessment of New Diagnostic Algorithms for Tuberculosis
Control. Clin Infect Dis. 2015 Oct 15;61(suppl 3):S126–34.
17. PintoM,TrajmanA,Steffen R,EntringerAP,PintoM,TrajmanA,et al.Cost analysis
of nucleic acid amplification for diagnosing pulmonary tuberculosis, within the context
of the Brazilian Unified Health Care System. J Bras Pneumol. 2015 Dec;41(6):536–8.
18. Durovni B, SaraceniV, van den Hof S,TrajmanA, Cordeiro-Santos M, Cavalcan-
te S, et al. Correction: Impact of Replacing Smear Microscopy with Xpert MTB/
RIF for Diagnosing Tuberculosis in Brazil: A Stepped-Wedge Cluster-Randomized
Trial. PLoS Med. 2015 Dec;12(12):e1001928.
19. Trajman A, Durovni B, SaraceniV, Menezes A, Cordeiro-Santos M, Cobelens F,
et al. Impact on Patients’Treatment Outcomes of XpertMTB/RIF Implementation
for the Diagnosis ofTuberculosis: Follow-Up of a Stepped-Wedge Randomized Cli-
nicalTrial. PloS One. 2015;10(4):e0123252.
20. de Camargo KR, Guedes CR, Caetano R, Menezes A,Trajman A.The adoption
of a new diagnostic technology for tuberculosis in two Brazilian cities from the
perspective of patients and healthcare workers: a qualitative study. BMC Health
Serv Res. 2015;15:275.
21. TrajmanA, Durovni B, SaraceniV, Cordeiro-Santos M, Cobelens F, van den Hof
S. High positive predictive value of Xpert in a low rifampicin resistance prevalence
setting. Eur Respir J. 2014 Dec;44(6):1711–3.
22. Durovni B, Saraceni V, Cordeiro-Santos M, Cavalcante S, Soares E, Lourenço
C, et al. Operational lessons drawn from pilot implementation of Xpert MTB/Rif
in Brazil. BullWorld Health Organ. 2014 Aug 1;92(8):613–7.
23. da Silva Antunes R, Pinto M,Trajman A. Patient costs for the diagnosis of tu-
berculosis in Brazil: comparison of Xpert MTB/RIF and smear microscopy. Int J
Tuberc Lung Dis Off J Int UnionTuberc Lung Dis. 2014 May;18(5):547–51.
24. Conde MB,EfronA,Loredo C,De Souza GRM,Graça NP,Cezar MC,et
al.Mo-
xifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind,
randomised, controlled phase II trial.The Lancet. 2009 Apr;373(9670):1183–9.
25. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, et al.Three
months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis infec-
tion in HIV co-infected persons.AIDS Lond Engl. 2016 Mar 17;
26. Menzies D, Long R, Trajman A, Dion M-J,Yang J, Al Jahdali H, et al. Adver-
se events with 4 months of rifampin therapy or 9 months of isoniazid therapy
for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008 Nov
18;149(10):689–97.
27. AsplerA, Long R,TrajmanA, Dion M-J, Khan K, Schwartzman K, et al. Impact
of treatment completion, intolerance and adverse events on health system costs in a
randomised trial of 4 months rifampin or 9 months isoniazid for latentTB.Thorax.
2010 Jul;65(7):582–7.
28. Scatena LM,Wysocki AD, Beraldo AA, Magnabosco GT, Brunello MEF, Ruffi-
no-Netto A, et al.Validity and reliability of a health care service evaluation instru-
ment for tuberculosis. Rev Saúde Pública. 2015;49:7.
29. Andrade RLP, Scatolin BE,Wysocki AD, Beraldo AA, Monroe AA, Scatena LM,
et al. [Tuberculosis diagnosis: primary health care or emergency medical services?].
Rev Saúde Pública. 2013 Dec;47(6):1149–57; discussion 1158.
30. Arakawa T, Magnabosco GT, Lopes LM, Arnaez MAA, Gavín MAO, Gallardo
MDPS, et al. Evaluation of the performance of Tuberculosis Control Programs in
Brazil and Spain: an integrative review of the literature. Cienc Saude Coletiva. 2015
Dec;20(12):3877–89.
31. Villa TCS, Ruffino-Netto A. Performance assessment questionnaire regarding
TB control for use in primary health care clinics in Brazil. J Bras Pneumol Publica-
ção Of Soc Bras Pneumol ETisilogia. 2009 Jun;35(6):610–2.
32. VillaTC, Ruffino-NettoA, Scatena LM,Andrade RLP, Brunello MEF, Nogueira
JA, et al. Health services performance forTB treatment in Brazil: a cross-sectional
study. BMC Health Serv Res. 2011;11(1):241.
33. Reis-Santos B, Gomes T, Locatelli R, de Oliveira ER, Sanchez MN, Horta BL,
et al. Treatment Outcomes in Tuberculosis Patients with Diabetes: A Polytomous
Analysis Using Brazilian Surveillance System. Fernandez-Reyes D, editor. PLoS
ONE. 2014 Jul 8;9(7):e100082.
34. do PradoT, Miranda A, de Souza F, dos Santos Dias E, Sousa LK, Arakaki-San-
chez D, et al. Factors associated with tuberculosis by HIV status in the Brazilian na-
tional surveillance system: a cross sectional study. BMC Infect Dis. 2014;14(1):415.
35. Marlow MA, Maciel ELN, Sales CMM, Gomes T, Snyder RE, Daumas RP,
et al. Tuberculosis DALY-Gap: Spatial and Quantitative Comparison of Disease
Burden Across Urban Slum and Non-slum Census Tracts. J Urban Health. 2015
Aug;92(4):622–34.
36. Reis-Santos B, Pellacani-Posses I, Macedo LR, Golub JE, Riley LW, Maciel EL.
Directly observed therapy of tuberculosis in Brazil: associated determinants and
impact on treatment outcome. Int JTuberc Lung Dis. 2015 Oct 1;19(10):1188–93.
37. dos Santos Dias E, do Prado TN, da Silva Guimarães AL, Ramos MC, Sales
CMM, de Fátima Almeida Lima E, et al. Childhood tuberculosis and human im-
munodeficiency virus status in Brazil: a hierarchical analysis. Int JTuberc Lung Dis.
2015 Nov 1;19(11):1305–11.
38. Maciel EL, Reis-Santos B. Determinants of tuberculosis in Brazil: from concep-
tual framework to practical application. Rev Panam Salud Pública Pan Am J Public
Health. 2015 Jul;38(1):28–34.
39. Torrens AW, Rasella D, Boccia D, Maciel ELN, Nery JS, Olson ZD, et al. Effec-
tiveness of a conditional cash transfer programme onTB cure rate: a retrospective
cohort study in Brazil.Trans R SocTrop Med Hyg. 2016 Mar;110(3):199–206.
40. StrabelliTMV, Siciliano RF, Castelli JB, Demarchi LMMF, Leão SC,Viana-Nie-
ro C, et al. Mycobacterium chelonae valve endocarditis resulting from contamina-
ted biological prostheses. J Infect. 2010 Jun;60(6):467–73.
41. Matsumoto CK, Chimara E, Ramos JP, Campos CED, Caldas PC de S, Lima
KVB, et al. Rapid tests for the detection of the Mycobacterium abscessus subsp.
bolletii strain responsible for an epidemic of surgical-site infections in Brazil. Mem
Inst Oswaldo Cruz. 2012 Dec;107(8):969–77.
42. Rabello MC da S, Matsumoto CK, deAlmeida LGP, Menendez MC, de Oliveira
RS, Silva RM, et al. First Description of Natural and Experimental Conjugation
between Mycobacteria Mediated by a Linear Plasmid. Johnson EA, editor. PLoS
ONE. 2012 Jan 3;7(1):e29884.
43. Leão SC,Viana-Niero C, Matsumoto CK, Lima KVB, Lopes ML, Palaci M, et
al. Epidemic of surgical-site infections by a single clone of rapidly growing myco-
bacteria in Brazil. Future Microbiol. 2010 Jun;5(6):971–80.